Five (3.7%) of the anti-VEGF-treated patients needed a second anti-VEGF treatment; 3 (2.2%) for reactivation of ROP and 2 (1.5%) for non-regression in plus disease. This evidence concerns the gene VEGFA and retinopathy of prematurity.